The Drying Pipeline

Both AstraZeneca and Novartis announced that drugs they had for depression and hypertension that were in the late stages of development have failed, reports Bloomberg, adding that AstraZeneca's drugs turned out to be disappointing while Novartis's tests on Tekturna were halted due to safety concerns. Further, Sanofi's multiple sclerosis drug, Aubagio, has not performed better than an older therapy.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.